Abzena

27.10.2025 • News • Pharma

Orion and Abzena Announce Exclusive Antibody Commercial License

Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, announced that Orion has obtained an exclusive focused commercial license to one of Abzena’s mAbs..

23.07.2025 • News • Pharma

Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

Abzena, an end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, recently announced that Geoffrey M. Glass has been appointed Chief Executive Officer, effective immediately.

Top-Feature

MOC – Event Center Messe München

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Abzena

Abzena

Orion and Abzena Announce Exclusive Antibody Commercial License

Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

Top-Feature

A successful concept on course for expansion — maintenance Munich 2025

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

20 Years of CHEManager International

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Interview

Stability in Motion

Newsletter & e-edition